SLC5A2 and atrial fibrillation: Findings regarding such outcomes were further supported by a meta-analysis of 39 randomized controlled trials including 107,770 participants, which also confirmed that SGLT-2 inhibitors significantly reduced the risk of AF and atrial flutter compared with placebo (RR 0.86; 95% CI, 0.77–0.95; I2 = 0%; p = 0.003).